Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Corcept Therapeutics (CORT) Tops Q1 EPS by 12c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus
May 4, 2020 4:51 PM EDTCorcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.34, $0.12 better than the analyst estimate of $0.22. Revenue for the quarter came in at $93.2 million versus the consensus estimate of $87.01 million.
Financial Highlights
Revenue of $93.2 million, a 44 percent increase from first quarter 2019GAAP diluted net income of $0.25 per share, compared to $0.15 per share in first quarter 2019Non-GAAP diluted net income of $0.34 per share, compared to $0.20 per share in first quarter 2019Cash and investments of $349.0 million, compared to $315.3 million in fourth quarter 2019Our commercial and medical affairs teams did an excellent... More
